What are the Future Directions for Efflux Pump Inhibitors?
Research is ongoing to develop more effective and selective EPIs with fewer side effects. Some promising approaches include:
- Nanotechnology: Using nanoparticles to deliver EPIs specifically to cancer cells, minimizing systemic toxicity. - Combination Therapy: Combining EPIs with other therapeutic agents to enhance efficacy and reduce resistance. - Targeted Therapy: Developing EPIs that target specific efflux pumps prevalent in certain types of cancer.
